N-Cyclohexyl-N-nitroso-harnstoff | 877-31-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N-Cyclohexyl-N-nitroso-harnstoff
• 英文别名: 1-Cyclohexyl-1-nitrosourea
• CAS: 877-31-6
• 化学式: C₇H₁₃N₃O₂
• 分子量: 171.199
• InChiKey: GPVGDGBVGWUGAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  75.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
  申请人：Coy H. David

  公开号：US20050070470A1

  公开（公告）日：2005-03-31

  Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic agent, detectable label or chelating group, and Q is a biologically active peptide. In peptide agents of the invention Y is optionally a hydrophilic polymer or peptide, and Z is a linking peptide bonded to Q at the amino terminus of Q, having two, three, four, or five, amino acid residues selected to link X to Q, while retaining the biological activity of Q. Methods of using these peptide agents in the diagnosis and treatment of diseases are also disclosed.

  披露了肽剂及其用途，它们是生物活性肽的类似物，例如生长抑素和蛙皮素。发明的化合物具有通式X-Y-Z-Q，其中X是细胞毒素、治疗剂、可检测的标签或螯合基团，Q是生物活性肽。在发明的肽剂中，Y是可选的水溶性聚合物或肽，Z是与Q的氨基端连接的连接肽，具有两个、三个、四个或五个氨基酸残基，选择将X连接到Q，同时保留Q的生物活性。还披露了使用这些肽剂在疾病的诊断和治疗中的方法。
• Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof
  申请人：Lee David Y-W

  公开号：US20080102026A1

  公开（公告）日：2008-05-01

  The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

  这项发明涉及一类具有次生碱性氮原子和携带一个或多个治疗剂、细胞毒剂、可检测标签或螯合基团的2-硝基咪唑化合物。具体而言，该发明提供了含有硼原子簇的用于硼中子俘获疗法（BNCT）的2-硝基咪唑化合物。这些2-硝基咪唑化合物可用于治疗缺氧情况，包括癌症、炎症和缺血等病症。这些弱碱性的2-硝基咪唑化合物靶向于缺氧组织，并提供整体组织浓度的增加。
• Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
  申请人：Schering AG

  公开号：EP1462119A1

  公开（公告）日：2004-09-29

  The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of cancer disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis of radiopharmaceutics into cells of the kidney and the subsequent radioinduced damaging of the kidney catabolism by blocking or interfering with the association or binding of radiotherapeutics and/or radiodiagnostics to the receptor megalin, a member of the LDL-receptor family. In another aspect of the present invention, the expression of megalin is altered, in order to prevent the endocytosis and cellular internalisation of radiopharmaceutics into cells of the kidney.

  本发明广泛涉及癌症疾病的治疗、诊断和预防。更具体地说，本发明涉及通过阻断或干扰放射性治疗药物和/或放射性诊断药物与受体megalin（低密度脂蛋白受体家族的成员）的结合或结合，防止放射性药物内吞进入肾脏细胞以及随后放射性诱导的肾脏分解代谢损伤的方法和组合物。本发明的另一个方面是改变megalin的表达，以防止放射性药物内吞和细胞内化到肾脏细胞中。
• APPLICATIONS OF ARCTIGENIN IN FORMULATING MEDICINES FOR PREVENTING OR TREATING DISEASES RELATED TO RED BLOOD CELL REDUCTION
  申请人：Lunan Pharmaceutical Group Corporation

  公开号：EP2626071A1

  公开（公告）日：2013-08-14

  Provided are applications of arctigenin in formulating medicines for preventing or treating diseases related to blood cell reduction, and preparations that contain arctigenin, particularly micro-emulsions that contain arctigenin. Experiments show that arctigenin can significantly increase the white cell counts after chemotherapy, especially the neutrophil granulocyte counts.

  本文提供了芹菜甙元在配制预防或治疗与血细胞减少有关的疾病的药物中的应用，以及含有芹菜甙元的制剂，特别是含有芹菜甙元的微乳剂。实验表明，芹菜甙元能显著增加化疗后的白细胞数量，尤其是中性粒细胞数量。
• Human serum albumin linkers and conjugates thereof
  申请人：Merrimack Pharmaceuticals, Inc.

  公开号：EP2860260A1

  公开（公告）日：2015-04-15

  The present invention relates to a human serum albumin (HSA) linker and binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.

  本发明涉及一种人血清白蛋白（HSA）连接体及其结合剂、诊断剂和治疗剂。还公开了 HSA 连接体共轭物的诊断和治疗应用方法及试剂盒。